stonks4u
Log inSign up free
VERA logo

VERA Vera Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$31.76
+0.13 (+0.41%)

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat…

Market Cap: $2.28Bveratx.com

Price

No data yet.

Signal Score (90d)

125
125
Aug 17Aug 17

Revenue

$0.00
$0.00
Sep 2021Jun 2026

Quote

Day Range
$31.20 – $32.70
52-Week Range
$21.15 – $56.05
Volume
$1.62M
Market Cap
$2.28B
50-Day Avg
$36.17
200-Day Avg
$38.98
Prev Close
$31.63
Open
$31.59

Valuation & Ratios

P/E Ratio
-10.87
EPS
$-4.66
P/B Ratio
5.38
P/S Ratio
0.00
Debt/Equity
0.13
Current Ratio
13.64
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-49.6%
Return on Assets
-40.8%
FCF Yield
-7.4%
EV/EBITDA
-10.20

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-299.62M$-4.66
2024$0.00$-152.15M$-2.75
2023$0.00$-95.99M$-2.25
2022$0.00$-89.06M$-3.35
2021$0.00$-32.61M$-2.43

Social Signal Score

75
5d
76
1 mentions
—
30d
75
1 mentions
—
60d
75
1 mentions
—
90d
75
1 mentions
—
news: 1

Earnings

Wed, Nov 4(in 3 months)

Consensus estimate $-1.61 per share

2of 7 quarters beat consensus

Typical surprise -5.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 10$-1.52 vs $-1.58beat
  • Thu, May 7$-1.69 vs $-1.33miss
  • Thu, Feb 26$-1.39 vs $-1.34miss
  • Wed, Nov 5$-1.26 vs $-1.20miss
  • Tue, Aug 5$-1.20 vs $-0.82miss
  • Tue, May 6$-0.81 vs $-0.75miss

Estimates and results for VERA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by VERA officers and directors.

Bought
$5.5m

5 trades

Sold
$11.5m

34 trades

  • Fordyce Marshallsold
    director, officer: PRESIDENT AND CEO·1,000 @ $40.78·$41k·Jul 7, 2026·filing
  • Fordyce Marshallsold
    director, officer: PRESIDENT AND CEO·32,550 @ $42.07·$1.4m·Jul 7, 2026·filing
  • Fordyce Marshallsold
    director, officer: PRESIDENT AND CEO·10,500 @ $42.86·$450k·Jul 7, 2026·filing
  • Fordyce Marshallsold
    director, officer: PRESIDENT AND CEO·2,200 @ $43.59·$96k·Jul 7, 2026·filing
  • Fordyce Marshallsold
    director, officer: PRESIDENT AND CEO·1,000 @ $40.78·$41k·Jul 7, 2026·filing
  • Fordyce Marshallsold
    director, officer: PRESIDENT AND CEO·32,550 @ $42.07·$1.4m·Jul 7, 2026·filing
  • Fordyce Marshallsold
    director, officer: PRESIDENT AND CEO·10,500 @ $42.86·$450k·Jul 7, 2026·filing
  • Fordyce Marshallsold
    director, officer: PRESIDENT AND CEO·2,200 @ $43.59·$96k·Jul 7, 2026·filing

61 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

VERAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsseekingalpha.com·5h ago·Positive

    Vera Therapeutics: FDA's eGFR Analysis Supports A Speculative Buy Vera Therapeutics is upgraded to Buy following TRUTAKNA's FDA approval and encouraging eGFR data. The FDA's exploratory eGFR analysis shows stable kidney function with TRUTAKNA, supporting the bull case ahead of full phase 3 data in Q3 2026. TRUTAKNA faces competition from Otsuka's VOYXACT and Vertex's povetacicept but enjoys a commercial head start and broad label.

    View source ↗